Syndesi Therapeutics

About:

Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions.

Website: https://www.syndesitherapeutics.com/

Twitter/X: syndesi_tx

Top Investors: Novo Holdings, Johnson & Johnson Innovation – JJDC, Fountain Healthcare Partners, S.R.I.W., V-Bio Ventures

Description:

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.